XTX Topco’s SAB Biotherapeutics SABS Stock Holding History

XTX Topco’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,555	Closed	-$22.3K	–	3055
2025 Q1	$22.3K	Buy	+16,555	New	+$38K	﹤0.01%	2119

Other funds holding SABS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Kovitz Investment Group Partners Chicago, Illinois $4.52B AUM 31.84% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

XTX Topco's SABS Position: Q2 2025 in Review

XTX Topco sold out of SAB Biotherapeutics (SABS) in Q2 2025, closing a stake of 16,555 shares — an estimated $22.3K sold.

XTX Topco first reported a position in SABS in Q1 2025 and held it in 1 quarter. The position peaked at $22.3K in Q1 2025. 25 funds tracked by Wall St. Rank hold SABS as of Q2 2025.

XTX Topco reported no remaining SAB Biotherapeutics position as of Q2 2025 after selling out during the quarter.
XTX Topco sold 16,555 SAB Biotherapeutics shares in Q2 2025, an estimated $22.3K.
XTX Topco first reported a position in SAB Biotherapeutics in Q1 2025 and held it in 1 quarter.
XTX Topco's SAB Biotherapeutics position peaked at $22.3K in Q1 2025.
25 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.